Shares of Veracyte (VCYT) surged 23% over the past week following a strong first-quarter earnings report that exceeded Wall Street expectations. The diagnostics company’s sales grew by 21%, and earnings per share skyrocketed, reflecting a net income margin increase from 6% to 21% year-over-year. Notably, Veracyte’s flagship product, Decipher, which detects prostate cancer, saw a 24% sales increase, while its thyroid cancer test, Afirma, grew by 12%. Management projects continued sales growth of 13% to 14% through 2026.
This robust performance positions Veracyte as a leader in the cancer-detection market, with its tests now considered the standard of care, bolstered by inclusion in the National Comprehensive Cancer Network’s guidelines. With a net cash balance of nearly $400 million against a market cap of $3.3 billion, the company is well-equipped for future growth and potential acquisitions.
For market professionals, Veracyte’s strong fundamentals and innovative pipeline make it a compelling growth stock to monitor, especially as it continues to expand its market share in oncology diagnostics.
Source: fool.com